Press Release

杭州多禧生物科技有限公司
HANGZHOU DAC BIOTECHNOLOGY CO., LTD

Hangzhou DAC Biotechnology Announces a Collaboration and License Agreement with Janssen for the Development of Novel Antibody-Drug Conjugates

Hangzhou, China, June 1st, 2022 -- Hangzhou DAC Biotechnology Co., Ltd. ("DAC Biotechnology") today announced a collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under the terms of the agreement, DAC Biotechnology will apply its innovative and proprietary antibody drug conjugate (ADC) platform to Janssen's proprietary antibodies with the aim to develop novel ADC products against up to five targets. The negotiation and finalization of the agreement was facilitated by Johnson & Johnson Innovation. DAC Biotechnology has also received an equity investment from Johnson & Johnson Innovation – JJDC, Inc.

"We are very proud to mark this important collaboration with Janssen," said Dr. Robert Yongxin Zhao, President and Chief Executive Officer of DAC Biotechnology. "After years of dedicated research and development, DAC technology has become a key player in the field of ADC innovation. Our advanced ADC platform, with abundant reserve of payload/linker pairs, conjugation technologies and CMC capabilities, enables us to build a deep pipeline of products, many of them being first-in-class ADCs. We are committed to bringing safe and efficacious medicines not only to patients in China, but also those around the world."

"The collaboration with Janssen is the very first collaboration milestone in our global roadmap. The combination of the license agreement and equity investment creates an exciting approach to progressing novel therapeutic innovations in overseas markets," Dr. Zhao continues.

With the aim to discover novel ADC products via license collaboration, DAC Biotechnology will fully leverage its intellectual properties and proprietary ADC platform, while Janssen will provide its expertise in proprietary antibodies, clinical development and global commercialization. Through the collaboration agreement, DAC Biotechnology is eligible to receive an upfront payment, cost reimbursement and milestone payments, plus royalties on worldwide sales for each selected product.

About DAC Biotechnology

Hangzhou DAC Biotechnology Co., Ltd. is a Chinese high-tech enterprise established in December 2012. The company was founded by several senior scientists who each has more than 20 years of experience in ADC field. DAC Biotechnology has established a broad and differentiated pipeline of 20 ADC drugs in total, 5 of which are under clinical development. In March 2021, the company closed Series C financing led by GL Ventures, CDG Capital, and CPE.

The ADC development platform of DAC is built on independent intellectual property rights in connection with more than 50 novel intelligent linkers (including site-specific conjugation) and 100 small molecule cytotoxic drugs, for which DAC owns 28 PCT patents in the ADC field and has applied for more than 400 patents over 21 countries and regions. The platform contains technologies of antibody generation, engineering and production process development, *in vitro* and *in vivo* ADC functional evaluation, drug and drug metabolites structure analyses, analytical method development and quality control, etc.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently

available to management. Forward-looking statements include information concerning the terms and development of the Company's collaboration with Janssen, the Company's business strategy, activities and financial prospects pursuant to collaboration agreements with third parties, and the design, progression and timing of its clinical trials, the ability of the single-arm UPLIFT cohort to enable registration, the potential benefits of our product candidates, and expectations regarding future clinical trial results based on data achieved to date. Forward-looking statements generally can be identified by terms such as "aims,""anticipates," "believes," "contemplates," "continues," "could," "estimates," "expects," "goal," "intends," "may," "on track," "opportunity," "plans," "poised for," "possible," "potential," "predicts," "projects," "promises to be," "seeks," "should," "target," "will," "would" or similar expressions and the negatives of those terms. Forward-looking statements represent management's beliefs and assumptions only as of the date of this press release. The Company's operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company's results of operations and whether these forward-looking statements prove to be correct include, among other things, that the Company's partner may not devote sufficient resources to the collaboration, that research, development or commercialization activities conducted pursuant to the Company's collaboration agreements prove to be unsuccessful, that preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later preclinical or clinical studies, and that the identification, development and testing of the Company's or its partner's collaboration.

Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements,even if new information becomes available in the future.

杭州多禧生物科技有限公司宣布与杨森就**新型抗体偶联药物（ADC 药物）达成合作和许可协议**

2022 年 6 月 1 日，中国杭州——杭州多禧生物科技有限公司（“多禧生物”）今天宣布与强生公司旗下杨森制药生物科技公司（“杨森”）达成合作和许可协议。根据该协议规定，多禧生物将应用其独有的 ADC 创新平台与杨森所提供的独有抗体，双方将就至多 5 个靶点开发新型 ADC 药物。强生创新协助促成该合作协议，强生创新旗下投资公司-JJDC 也对多禧生物进行了股权投资。

“首先，能与杨森合作，我们倍感荣幸。”多禧生物董事长兼 CEO 赵永新博士表示，“经过多年的艰苦创业和匠心深耕，多禧生物已成为 ADC 创新药领域的重要成员。我们的 ADC 技术平台涵盖品类丰富的细胞毒素小分子和连接子、多种偶联技术和强大的 CMC 能力，这也是多禧生物探索和开发新型 ADC 药物的基石。我们致力于为中国及全球的癌症患者提供安全有效的 ADC 药物。”

赵博士还表示：“与杨森的合作是我们全球战略的第一个里程碑。这种许可合作加股权投资的‘组合拳’模式是中国创新药企业扬帆出海的新途径。”

以开发 ADC 创新产品为目标，通过此次协议合作，多禧生物将充分利用其自主知识产权和专有 ADC 平台，杨森将提供其独有抗体并推动临床开发和商业化。根据协议，多禧生物将获得预付款、成本报销和里程碑付款，以及产品全球销售额的特许权使用费。

关于杭州多禧生物科技有限公司

杭州多禧生物科技有限公司成立于 2012 年 12 月，是中国国家级高新技术企业。公司由多位在 ADC 领域拥有 20 多年经验的资深科学家创立。多禧生物目前拥有 20 条处于不

同研究阶段的 ADC 管线，其中 5 款 ADC 药物已经处于临床开发阶段。2021 年 3 月，公司完成了由高瓴创投、晨岭资本和 CPE 领投的 C 轮融资。

多禧生物的 ADC 开发平台具有自主知识产权，涵盖了 50 多个新型智能连接子（包括定点偶联技术）和 100 多个小分子药物。多禧生物在 ADC 领域拥有 PCT 专利 28 项，在 21 个国家和地区申请专利 400 多项。多禧生物的 ADC 平台还包括抗体发现和生产工艺、ADC 药物动物体外和体内功能评价体系、药物和药物代谢物结构分析、质量控制所需的分析方法开发和验证体系等技术。

前瞻性陈述

本新闻稿包含联邦证券法意义上的“前瞻性”声明。这些前瞻性陈述不是对历史事实的陈述，而是基于管理层的信念和假设以及管理层目前可获得的信息。前瞻性陈述包括有关公司与 Janssen 合作的条款和发展、公司根据与第三方的合作协议的业务战略、活动和财务前景的信息，以及临床试验的设计、进展和时间安排、能够注册的单臂 UPLIFT 队列、我们的产品候选者的潜在好处以及基于迄今为止获得的数据对未来临床试验结果的预期。前瞻性陈述通常可以通过“目标”、“预期”、“相信”、“考虑”、“继续”、“可能”、“估计”、“预计”、“目的是”、“打算”、“可能”、“在轨道上”、“机会”、“计划”、“准备”、“可能”、“潜力”、“预测”、“项目”、“承诺”、“寻求”、“应该”、“目标”、“将要”、“将会”或类似的表达方式和这些术语的否定形式等术语来识别。前瞻性陈述仅代表管理层截至本新闻稿发布之日的信念和假设。公司的经营涉及风险和不确定性，其中许多不在其控制范围内，其中任何一项或其中任何一项或组合可能对其经营业绩以及前瞻性陈述最终被证明是正确的产生重大影响。可能对公司的经营业绩产生重大影响的因素以及这些前瞻性陈述是否被证明是正确的包括，除其他外，公司的合作伙伴可能没有为合作投入足够的资源，研究、开发或商业化活动根据公司的合作协议被证明是不成功的，临床前测试或早期临床结果可能无法预测正在进行或以后的临床前或临床研究的结果或成功，以及公司或其合作伙伴合作的识别、开发和测试。

除法律要求外，本公司不承担公开更新这些前瞻性陈述或更新实际结果可能与前瞻性陈述中预期的结果大不相同的原因的义务，即使未来有新信息可用。

Contact:

Investor & Media Contact

Amos Xu Chen

0571-56050590

Chenxu@dacbiotech.com